LobbyingZero Prostate Cancer lobbying by quarter
Zero Prostate Cancer's latest lobbying report covers Q2 2026, at $123.7K. The four quarters Q4 2025–Q3 2026 total $473.7K. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Health Issues.
Zero Prostate Cancer
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $473.7K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $120K | 1 |
| Q1 2023 | $150K | 1 |
| Q2 2023 | $120K | 1 |
| Q3 2023 | $80K | 1 |
| Q4 2023 | $90K | 1 |
| Q1 2024 | $110K | 1 |
| Q2 2024 | $80K | 1 |
| Q3 2024 | $90K | 1 |
| Q4 2024 | $130K | 1 |
| Q1 2025 | $100K | 1 |
| Q2 2025 | $130K | 1 |
| Q3 2025 | $130K | 1 |
| Q4 2025 | $130K | 1 |
| Q1 2026 | $220K | 1 |
| Q2 2026 | $123.7K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$450.9K · 15 reports
- Health issues$450.9K · 15 reports
- Insurance$450.9K · 15 reports
- Veterans$450.9K · 15 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Veterans Affairs, Dept of (VA)11 reports
- Health Resources & Services Administration (HRSA)5 reports
- Health & Human Services, Dept of (HHS)4 reports
- White House Office3 reports
- Centers For Disease Control & Prevention (CDC)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseZero Prostate Cancer | $1.8M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | In-house | $123.7K |
| 04/17for Q1 | In-house | $220K |
| 01/20for Q4 2025 | In-house | $130K |
| 25/10/14for Q3 2025 | In-house | $130K |
| 25/07/13for Q2 2025 | In-house | $130K |
| 25/04/20for Q1 2025 | In-house | $100K |
| 25/01/20for Q4 2024 | In-house | $130K |
| 24/10/16for Q3 2024 | In-house | $90K |
| 24/07/11for Q2 2024 | In-house | $80K |
| 24/04/24for Q1 2024 | In-house | $110K |
| 24/01/16for Q4 2023 | In-house | $90K |
| 23/10/20for Q3 2023 | In-house | $80K |
| 23/07/10for Q2 2023 | In-house | $120K |
| 23/04/20for Q1 2023 | In-house | $150K |
| 23/01/19for Q4 2022 | In-house | $120K |